D3 Bio to Present First-Line NSCLC Phase2 Data for Elisrasib (D3S‑001) in Clinical Science Symposium at the 2026 ASCO Annual Meeting
May 12, 2026
SHANGHAI, May 12, 2026 — D3 Bio Inc. (“D3Bio”), a global clinical‑stage biotechnology company dedicated to developing innovative oncology therapeutics, today announced that first-line NSCLC data for Elisrasib (D3S‑001), its next‑generation GDP‑bound KRAS G12C inhibitor, will be presented in a Clinical Science Symposium at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, IL.
Presentation Details
Title: Elisrasib (D3S‑001), a next‑generation GDP‑bound KRAS G12C inhibitor, as first‑linetherapy for KRAS G12C mutation‑positive non–small cell lung cancer (NSCLC)
Abstract #: 8511
Session Name: Clinical Science Symposium
Session Title: Is the Juice Worth the Squeeze: Challenges in Combination Therapyfor Non–Small Cell Lung Cancer
Session Date: May 30, 2026
Presentation Time: 8:48-9:00 AM CDT
Location: Arie Crown Theater
“Selection for a Clinical Science Symposium presentation at ASCO underscores the scientific rigor and clinical promise of Elisrasib,” said Dr. George Chen, Founder, Chairman and Chief Executive Officer of D3 Bio. “These first‑line NSCLC data further validate Elisrasib’s potential as a best‑in‑class next‑generation KRAS G12C inhibitor and reinforce our commitment to building a fully integrated, KRAS‑focused portfolio to address high unmet needs for patients with KRAS‑driven solid tumors.”
About Elisrasib (D3S‑001)
Elisrasib is a next-generation KRAS G12C inhibitor designed for rapid, complete, and selective target engagement. It covalently binds the GDP-bound (OFF) form of KRAS G12C, effectively blocking nucleotide cycling and suppressing oncogenic signaling. Preclinical studies show robust potency, complete KRAS G12C engagement at clinically relevant exposures, and CNS penetration capability. Elisrasib is currently being evaluated globally in a Phase 2 monotherapy and combination trial across KRAS G12C–mutant solid tumors including NSCLC, CRC, and others.
About D3 Bio
D3 Bio is a global biotechnology company focused on the discovery, development, and registration of novel oncology and immunology therapies with first or best in class potential. Guided by deep clinical insight and biomarker-driven‑strategies, the Company is advancing a pipeline of programs targeting key oncogenic drivers and immune pathways. D3Bio owns global rights to all its programs.
For more information, please visit www.d3bio.com.
Media / Investor Contact: